

CLINICO-FUNCTIONAL ASSESSMENT OF COPD COURSE IN PATIENT WITH DIFFERENT REVERSIBILITY OF BRONCHIAL OBSTRUCTION

Y. M. Mostovoy, K. D. Dmytriiev, N. S. Slepchenko

Vinnitsia National Pirogov Memorial Medical University, Vunnytsia, Ukraine

Abstract. *Materials and methods.* 62 patients with diagnosis of chronic obstructive pulmonary disease (COPD) were included in the study, average age was 65.9 years, there were 21 women (33.9 %) and 41 men (66.1 %). According to the results of spirometric investigation 2 groups were formed. First group included patients, who had low reversibility level – $< 6\%$, there were 26 such patients (42 %). Second group included patients, who had high reversibility level $\geq 6\%$, there were 36 such patients (58 %). This distribution was used by the investigators for the comparison of a set of historical, clinical, functional value in these groups. *Results.* A number of exacerbations was significantly higher in patients of the first group ($2.86, p < 0.05$). These patients were treated in the in-patient conditions more often compared to the patients of second group ($1.73, p < 0.05$). Assessment of the dyspnea severity using mMRC scale revealed its high degree at visit 1 in patients of the first group, that consisted ($2.38, p < 0.05$). Despite different degree of the bronchial obstruction, patients had a similar response to tiotropium/olodaterol according to CAT questionnaire. Administration of tiotropium/olodaterol lead to the significant improvement of quality of life in both groups. Patients of the second group had significant improvement of FEV_1 ($54.9, p < 0.01$) and FVC ($84.0, p < 0.01$) values between visit 1 and 2. *Conclusions.* Patients with COPD with low reversibility of bronchial obstruction are the special group of patients with COPD. Obtained data allow to select this group as such requiring closer monitoring and treatment of the main disease, as well as comorbidities.

Key words: COPD, quality of life, spirometry, tiotropium/olodaterol.

Yurii M. Mostovoy

Vinnitsia national medical university named after M. I. Pyrogov MOH of Ukraine

Chief of internal diseases propaedeutics chair

Doctor of medicine, professor,

28/59, 600-richia, Vinnitsia, 21021, Ukraine,

yura.mostovoy@gmail.com

Asthma and Allergy, 2020, 4, P. 25–30.